Purpose: To define the activity and toxicity of preoperative chemotherapy and postoperative concomitant chemoradiotherapy in patients with carcinoma of the esophagus, and to determine the effect on survival in patients treated with this approach.
Introduction
Carcinoma of the esophagus remains a particularly difficult disease to manage, with poor survival rates due to a high incidence of locoregional and/or distant failure [1] [2] [3] . Patients often present with a marginal performance status due to poor nutrition or comorbid conditions, and commonly develop respiratory complications such as malignant fistulae and aspiration pneumonitis. In recent years, many studies have been performed examining the role of chemotherapy when combined with either surgical resection, definitive radiotherapy, or both in the management of this disease.
In 1987, we designed a study to evaluate the role of preoperative induction chemotherapy and postoperative concomitant chemoradiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. This treatment program was designed based on our previous experience with induction chemotherapy with cisplatin, 5-fluorouracil (5-FU), and leucovorin (PFL) as well as concomitant chemoradiotherapy with hydroxyurea and 5-FU in patients with head and neck cancer [4] [5] [6] . The objectives of this study were: 1) to define the response rate following two courses of preoperative chemotherapy; 2) to define the toxicities of concomitant chemoradiotherapy; and 3) to determine the feasibility and overall effect of this multimodality treatment approach on survival. We present a long-term analysis of this trial.
Patients and methods

Eligibility criteria
Patients with untreated histologically-documented carcinoma of the esophagus or gastroesophageal junction without evidence of distant metastases were eligible. Patients were required to have a performance status (CALGB) of < 2, a creatinine clearance of > 50 ml/min, and no significant underlying cardiopulmonary disease or hepatic dysfunction. All patients underwent complete history and physical examination, hematologic and chemical screening, 24-hour urinary creatinine clearance, chest X-ray, barium esophagram, computed-tomographic (CT) scan of the thorax and upper abdomen, bone scan, and gastroesophageal endoscopy by a thoracic surgeon prior to study entry. Patients with mid-esophageal lesions proximal to the level of the carina also underwent fiberoptic bronchoscopy to assess for the presence of airway infiltration or invasion. All patients reviewed and signed a detailed informed consent document in accordance with policies set forth by our institutional review board.
Treatment plan
Induction chemotherapy consisted of two cycles of cisplatin, 5-FU infusion and leucovonn (PFL). Cisplatin was administered intravenously over six hours at a dose of 100mg/m 2 on day 1, followed immediately by a five-day continuous infusion of 5-FU, 800 mg/m 2 /day. Leucovorin 100 mg/m 2 was administered orally every four hours for five days during the 5-FU infusion [4] , Cycle 2 was begun on day 22.
Surgical resection was performed if feasible. It was planned to be done not later than four weeks after beginning cycle 2 of induction chemotherapy, i.e., by day 49. Initial surgery (prior to chemotherapy) was also allowed in order to facilitate enrollment of patients referred from outside institutions.
Concomitant chemoradiotherapy (FHX), after surgical resection or after PFL induction if the patient was unresectable, consisted of daily radiotherapy for five days in 200-cGy fractions, combined with 5-FU 800 mg/m 2 continuous infusion daily for five days, starting approximately eight hours prior to the first radiotherapy treatment of the week. Hydroxyurea, 1 g, was administered orally twice daily for the five days, with the morning dose timed to be given approximately two hours before the radiotherapy treatment for that day. The first two patients treated also received leucovorin with the fluorouracil [6] . Combined treatment was given every other week for five or six total treatment weeks, with the total dose of radiation being between 5000 and 6000 cGy [5, 6] , It was planned to begin within four to eight weeks of surgical resection Radiation fields were designed to encompass the primary tumor and regional lymphatics including the supraclavicular and celiac nodes. Attempts were made to use the same radiation therapy fields in both the pre-operative and post-operative setting. In the post-operative setting fields were modified to include the anastomosis.
The total dose for post-operative cases was 50 Gy delivered in 2 Gy fractions. The initial 40 Gy was delivered with an AP-PA technique followed by an additional 10 Gy delivered with an AP-oblique technique. This field arrangement was used to minimize the dose to normal lung while keeping the dose to the spinal cord within acceptable limits. Patients with known residual disease following surgery or unresectable disease received 60 Gy.
Assessment of response and survival
Response to induction chemotherapy was assessed by repeat esophagram, CT scan, and endoscopic measurement of residual disease. Complete response was defined as complete disappearance of all evidence of disease. Partial response was defined as shrinkage by 50% or more in the length of tumor in the esophagus, or in thickness of esophageal tumor as measured on cross-sectional cuts on a CT scan. Stable disease was defined as shrinkage of less than 50% or no change in the parameters noted.
Survival was measured from the first day of induction chemotherapy, including in five patients who underwent surgical resection as their initial treatment. Time to progression was defined as the time from the first day of induction chemotherapy until documentation of progressive locoregional or distant tumor, or toxic death. Patients who died from other causes or were lost to follow-up with respect to tumor progression were censored from the time to progression analysis. Follow-up is available through January 1998.
Results
Patient characteristics
Between May 1987 and March 1993, 46 patients were entered on this study. The pre-treatment characteristics are shown in Table 1 . As noted, the number of patients with squamous cell carcinoma and adenocarcinoma Responses assessed by clinical criteria.
were nearly equal. Five patients were entered after undergoing surgical resection a median of 43 days earlier (range 33-68 days).
Induction chemotherapy
Tumor response to induction PFL chemotherapy, as determined by clinical criteria, is shown in Table 2 . The overall response rate among the 41 patients who received PFL before surgery was 41%. The toxicities of PFL chemotherapy for all patients are shown in Table 3 . The most frequent toxicities encountered were mucositis and granulocytopenia. Thrombocytopenia, diarrhea, and renal insufficiency were uncommon. One patient died on day 10 of the first cycle of PFL from neutropenic sepsis and electrolyte abnormalities. Two additional patients refused the second cycle of PFL induction because of severe mucositis; 11 patients had a treatment delay before cycle 2, with a median duration of seven days (range 2-21 days).
Surgical outcome (Figure 1)
Thirty-seven patients underwent surgical resection, including five patients who had a resection prior to PFL chemotherapy. Of 32 patients operated after PFL, two were unresectable and 30 completed resection. Gross residual disease remained in two patients, and micro- Table 3 . Toxicity of induction chemotherapy (PFL, n = 46 patients). Surgery ( Abbreviations: FHX -5-FU, hydroxyurea, radiotherapy; LT f/u -lost to follow-up; XRT -radiotherapy; PD -progressive disease; PFLcisplatin, 5-FU, leucovorin scopic marginal disease was present in four. The other 25 patients had complete resections. There were two postoperative deaths: one from a massive pulmonary embolus eight days postoperatively, and one from respiratory failure and sepsis associated with a malignant pleural effusion 37 days postoperatively. The surgical experience in this group of patients has been published previously [7] .
Grade
The results of pathologic evaluation were as follows: one patient with squamous cell carcinoma had no residual tumor; five patients, two with squamous carcinoma and three with adenocarcinoma, had minimal microscopic tumor only; and 24 had gross residual tumor in the surgical specimen.
Concomitant chemoradiotherapy
Thirty-three patients underwent concomitant chemoradiotherapy, 28 after resection and PFL, and five after PFL without resection. The toxicities are shown in Table 4 . Mucositis and esophagitis and granulocytopenia were the most common toxic effects. One patient had grade 3 skin toxicity (hand-foot syndrome). Five patients had clinically significant radiation pneumonitis, which was fatal in one. Of the 13 patients not undergoing chemoradiotherapy, five underwent radiotherapy alone (patient preference or distance from the University Medical Center), three died (after PFL or postoperatively), one patient progressed early, one refused radiotherapy, and three were lost to follow-up.
Pattern of failure and survival
With a minimum follow up of 58 months, the median survival for the entire group of 46 patients is 16 months. For the patients with squamous cell carcinoma, the median survival is 29 months; for the patients with adenocarcinoma, the median survival is 12 months. The survival curves are shown in Figures 2 and 3 . Eleven patients are still alive, seven with squamous carcinoma (at 63, 73, 73, 85, 88, 92, and 108 months) and four with adenocarcinoma (at 58, 69, 70, and 75 months). For the eight patients who did not undergo surgical resection or were resectable, the median survival was 10 months (5-71 months). Locoregional recurrences were the site of failure in 11 patients, including in five patients who were not resected, and distant metastases were the site of failure in 11. Three patients died from unrelated illnesses, one died from a second primary (gastric) cancer, four died from treatment toxicity (one during PFL, one from radiation pneumonitis, two from postoperative complications), and the details of the outcome in five patients are unknown.
Discussion
Combined modality therapy for patients with carcinoma of the esophagus has been extensively evaluated. Recent randomized studies indicate that concomitant chemoradiotherapy can result in a statistically significant increase in survival.
Since patients with esophageal cancer fail both within and outside of the radiation field, we designed this phase II study to include systemic induction chemotherapy and radiation-enhancing concomitant chemoradiotherapy. Our results indicate that the overall sequencing of this intensive approach was feasible, even when using an aggressive induction chemotherapy regimen such as the PFL combination. The administration of all three planned treatment segments was feasible in the majority of resectable patients, although toxicity was substantial. However, the study cohort was heterogeneous and in- eluded some patients who underwent initial surgery. With a minimum follow-up time of 58 months, we report encouraging long-term survival results although the overall survival does not appear to be superior to those achieved in larger multi-institutional settings with less intensive regimens [8] [9] [10] [11] .
Patients with squamous cell carcinoma had a favorable median and long-term survival time while patients with adenocarcinoma appeared to do less well (median survival 29 and 12 months, respectively). Since the study assumed that both groups would respond similarly and the overall study cohort was only 46 patients, these differences may be due to the limited number of patients for each histology. It could also indicate a true difference in response activity of squamous cell cancers to the specific regimens utilized. Ajani et al. described 26 patients with adenocarcinoma treated with preoperative etoposide, doxorubicin. and cisplatin, in whom the median survival was 12.5 months [12] . By contrast, the same investigators reported on a series of 34 patients with squamous carcinoma, treated with preoperative cisplatin and fluorouracil, in whom the median survival was 28 months [13] . These data suggest that adenocarcinoma may have a worse prognosis than squamous cell carcinoma, although this has not been found in all series [14] . Blot et al. have noted the increasing incidence of adenocarcinoma of the esophagus and gastric cardia, reporting that its rate of increase in frequency exceeds that of all other cancers [15] . This observation lends particular importance to the possibility of inferior treatment results in patients with adenocarcinoma. Future studies should focus attention on this possibility.
Induction chemotherapy has been investigated in a large number of phase II studies including its administration prior to surgery/radiotherapy or radiotherapy alone. It has been shown to be feasible in both settings [16, 17] . The value of preoperative induction chemotherapy has been studied in randomized trials; however, conclusive data supporting its routine use are not yet available [18, 19] . At a response rate of 41%, the observed activity of PFL was not much higher than that reported with other regimens, while toxicities were increased.
Concomitant chemoradiotherapy has also been investigated, both as primary treatment and in the preoperative setting [8-11, 14, 20-23] . Forastiere et al. reported on 41 patients treated with preoperative concomitant chemotherapy (cisplatin, vinblastine, fluorouracil) and 37.5-45 Gy radiotherapy [14] . With a median follow-up of more than six years, the median survival of the whole group was 29 months, (32 months for adenocarcinoma and 23 months for squamous carcinoma). Twenty-four percent of patients resected had pathological complete responses. At five years, 34% of all the patients were alive; of those with complete pathological responses, the median survival was 70 months, with 60% alive at five years. Recently, Minsky et al. reported on an Intergroup trial of induction chemotherapy with cisplatin plus 5-FU followed by concomitant cisplatin-fluorouracilradiotherapy (64.8 Gy) [21] . Their study sequence was similar to that tested in this report. Forty-five patients were treated, with five treatment-related deaths. The median survival was 20 months and the authors concluded that further testing of their regimen was not indicated.
Conclusive phase III trials examining the role of concomitant chemoradiotherapy in patients with esophageal carcinoma have been published. The RTOG compared radiotherapy alone with radiotherapy plus cisplatin and 5-FU. There was a significant advantage favoring the combined modality group [8, 9] . The latter had a median survival of 14.1 months compared to 9.3 months for the radiotherapy alone group [9] .
Walsh et al. reported on a randomized study comparing preoperative concomitant chemotherapy (fluorouracil, cisplatin) and 40 Gy radiotherapy to resection alone in 113 patients with esophageal adenocarcinoma [10] . The median survival for the combined modality group was 16 months, compared to 11 months for the surgeryalone group. Three-year survivals were 32% and 6%, respectively.
In a report of a randomized trial of 100 patients comparing preoperative chemoradiotherapy (cisplatin, vinblastine and fluorouracil with 45 Gy delivered by twice-daily fractionation) to surgical resection alone, Urba et al. found virtually identical median survival times for the two groups (1.4 years). The three-year survival rates, however, were 32% versus 15%, favoring the addition of chemoradiotherapy (P = 0.07) [11] . Similarly, in an ECOG study of 118 patients comparing radiotherapy alone vs. radiotherapy plus 5-FU and mitomycin, the median survival was 14.9 months for the combined modality arm, compared with nine months for the control arm in a preliminary analysis [22] . Bosset et al., however, recently reported that preoperative cisplatin and concomitant radiotherapy (37 Gy) added no significant survival benefit, although disease-free survival was improved with chemoradiotherapy [23] .
In this study, we have shown that induction chemotherapy and postoperative concomitant chemoradiotherapy can be added safely to surgical resection for carcinoma of the esophagus. However, our results appear quite similar to those reported in the randomized studies of Walsh et al. and Herskovic et al. [8] [9] [10] [11] . The additional value of two cycles of induction chemotherapy is unclear, and may only add toxicity and lengthen the overall treatment duration as also shown by Minsky et al. [21] . While we remain intrigued with the possible sequence of induction chemotherapy (addressing locoregional and systemic disease) followed by concomitant chemoradiotherapy (to consolidate locoregional control), we do not recommend further testing of the specific regimen reported here. It is possible that the taxanes and other recent drugs will have a greater role. Some of these drugs have already been shown to have antitumor activity in advanced esophageal carcinoma, and need to be used in trials of combined modality therapy [24, 25] .
